Key insights
- Abbott Laboratories' CFO significantly increased his stake in the company, purchasing over $200,000 in stock near its 52-week low. This insider buying, coupled with an InvestingPro analysis suggesting undervaluation, could signal a potential positive shift for ABT. Despite mixed Q1 results and some analyst target reductions, the CFO's confidence may offer a bullish signal for the stock, especially given its long dividend history.
Philip P. Boudreau, Executive Vice President and Chief Financial Officer of Abbott Laboratories (NYSE:ABT), recently increased his indirect holdings in the company’s common stock. According to a Form 4 filing, Mr. Boudreau’s spouse purchased 2,200 common shares on April 23, 2026. These shares were acquired at a price of $91.50 per share, totaling $201,300.
On the same date, Mr. Boudreau also acquired 8,909 common shares indirectly through the Abbott Laboratories Stock Retirement Trust, which is part of a profit-sharing trust. These shares were acquired at a price of $92.04 per share. Following this transaction, his indirect holdings in the trust totaled 9,276 shares.The insider purchases come as Abbott trades near its 52-week low of $90.72, down 25% year-to-date. According to InvestingPro analysis, the stock appears undervalued at current levels, placing it among opportunities on the most undervalued stocks list. InvestingPro offers 11 additional exclusive tips for Abbott, including insights on the company’s 56-year dividend payment streak.
After these transactions, Mr. Boudreau directly holds 71,172 common shares of Abbott Laboratories.
In other recent news, Abbott Laboratories has released its first-quarter results, which have led to several analyst firms adjusting their price targets for the company. The company’s worldwide sales increased by 1% compared to consensus expectations, with adjusted earnings per share meeting projections. However, the results showed weaker performance in the respiratory segment and diabetes business, which contributed to the revenue missing expectations on an organic growth basis.
Leerink Partners lowered its price target for Abbott Laboratories to $106, maintaining a Market Perform rating, while Bernstein SocGen Group reduced its target to $110, keeping an Outperform rating. Piper Sandler also adjusted its price target to $115, citing underperformance in the medical device segment, particularly in diabetes sales, but maintained an Overweight rating. TD Cowen lowered its target to $115, highlighting reduced organic guidance and weakness in respiratory and Libre products. Meanwhile, RBC Capital adjusted its price target to $130, maintaining an Outperform rating, and pointed to mixed results in Abbott’s major segments, including MedTech-Diabetes and surgical products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates ABT alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ABT is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?